Research programme: bis-anthracycline therapeutics - CallistoAlternative Names: WP 760
Latest Information Update: 19 May 2011
At a glance
- Originator Callisto Pharmaceuticals
- Mechanism of Action DNA inhibitors; RNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Jul 2005 Preclinical trials in Cancer in USA (unspecified route)